Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + docetaxel in biomarker-selected relapsed or refractory metastatic colorectal adenocarcinoma
2013-005086-40Phase 2Active
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Feb 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and gemcitabine in colorectal adenocarcinoma and metastatic colorectal adenocarcinoma (mCRC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Overall response rate. Started Feb 2014; status: active.
02
Drugs
docetaxelgemcitabine
03
Conditions
colorectal adenocarcinomametastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2013-005086-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005086-40.